.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
For this episode of CM Conversations, our Director of Operations Tom Maskill spoke with QIAGEN CEO Thierry Bernard.
For decades, we’ve been talking about how NGS will change the world. But what if NGS was only the start?
.jpg)
Only 30% of executive positions and 18% of board seats are held by women in biotech. I spoke to industry expert, Melissa Gammell, to find out where we're going wrong, how we get more women into biotech and how we keep them there.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
Cytosurge's tiny syringes are a game changer for the single cell genomic and gene editing applications; since patenting the technology in 2009 the company has gone from strength to strength.
.jpg)
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
As businesses prioritise the wellbeing of their employees, the concept of working a 4 day week is shifting from distant pipedream to reality for a range of organisations around the world.
Even if you’ve been through the process, you may not be aware of exactly what goes into M&A deals. Today, we’ve tried to look into that in a little more detail with Transaction Liability Team Leader Grant Hollis from CFC Underwriting,
When we talk about genomics hubs, then usually we’d be talking about Oxbridge, Boston or Silicon Valley thanks to success stories like 10x Genomics, Illumina or Solexa. However, as the technology needed to conduct genomic R&D becomes more accessible
In the US alone, a report by the Centers for Disease Control and Prevention (CDC) in March this year highlighted how 2.8 million antibiotic-resistant infections occur each year, leading to the deaths of more than 35,000 people.
One of the biggest partnering events in the life science calendar Bio-Europe Spring, was scheduled to take place in Paris from March 23 – 27 this year. That all changed with the emergence of COVID-19...
We’ve been waiting for the $100 genome for a long time and now it’s here. Check out what our consultants had to say about this big news and other landmark announcements at AGBT 2020.
There’s so much more to the UK biotech scene than just London and Cambridge. In the North, we're surrounded by many fascinating companies who’re innovating and conducting crucial research.
It's humbling to see how the life science community has come together to combat the coronavirus. Here's what's happening in diagnostics.
.png)
The race is on to get CRISPR into diagnostics. This would bring countless benefits including quicker and more accurate results for both infectious and non-infectious disease.
NGS has been on a fascinating journey, featuring numerous pioneering players all racing to get their technology to market. A little over 20 years ago, the race began…
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
Our Principal Consultant, Adam Butler, talks about the miracles of Stem Cell therapy, the issues surrounding it and the most high-profile case in the treatments' existence.
In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.
Since the early 2000’s, before Solexa sequenced bacteriophage phiX-174, single cell genomics has been tipped to become one of the most exciting technologies in genetic analysis.
There’s always a ‘next big thing’ in the healthcare, research and life sciences industries but the emergence and development of the biotech sector is one of the few that has the chance to change the world.
Infectious diseases claim the lives of thousands of people around the world every year. Though methods of diagnosis and treatment have come a long way in recent years, there is still work to do.
In November this year, as first broken by the MIT Technology Review, it was revealed that Chinese scientist He Jiankui had been conducting gene-editing research using CRISPR technology on foetuses as late as 24 weeks into pregnancy.
Just over a year ago, I wrote this article. It was all about the companies who I thought were attempting to compete with, Illumina in the NGS market. Safe to say that last Friday’s announcement that Illumina are acquiring Pacific...
The Next Generation Sequencing (NGS) industry is still young, but as more companies develop their own systems we’re now seeing new applications emerge for the technology. A wide variety of businesses and industries are thinking outside the tradit...
Collaborations can produce amazing results. When the Wright Brothers put their heads together, they learned how to fly. When Lennon and McCartney met in 1957, pop music was changed forever.
In the digital age we live in, information is everything. Facebook make billions through advertising, purely because of the information they collect from us about our habits, searches and interests.
Next Generation Sequencing (NGS) has been the biggest development in biologics since Friedrich Mierscher first found and isolated DNA. The ground breaking technology has given us the ability to truly see what it is that makes us human.
Until very recently, the most talked about and desirable technology within molecular biology was Next Generation Sequencing (NGS). NGS was the technology sales reps wanted to sell and molecular biologists wanted to work with. Recently though,...
